Education
About Us
Working with TipRanks
Follow Us
Mind Medicine (DE:MMQ)
FRANKFURT:MMQ
MMQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range€4.29 - €9.80
Previous CloseN/A
Volume187.00
Average Volume (3M)119.00
Market Cap
$585.61M
Enterprise Value€412.10M
Total Cash (Recent Filing)$182.99M
Total Debt (Recent Filing)$41.19M
Price to Earnings (P/E)―
Beta1.40
Next Earnings
Nov 12, 2025EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding76,087,944
10 Day Avg. Volume43
30 Day Avg. Volume119
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.03
Price to Sales (P/S)0.00
P/FCF Ratio-6.20
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$22.16Price Target Upside179.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMindMed continues to advance its late-stage pipeline with all three Phase 3 trials for MM120 actively enrolling.
Financial PositionMindMed ended with approximately $238M of cash, which is expected to provide cash runway into 2027.
Regulatory SupportBreakthrough Therapy designation granted by the FDA to MM120 in GAD supports the company's strategic position.
Bears Say
Market PerceptionMindMed continues to be a top choice in the psychedelic sector, with expectations of significant stock movement upon successful trial results.
Mind Medicine News
MMQ FAQ
What was Mind Medicine’s price range in the past 12 months?
Mind Medicine lowest stock price was €4.29 and its highest was €9.80 in the past 12 months.
What is Mind Medicine’s market cap?
Mind Medicine’s market cap is $585.61M.
When is Mind Medicine’s upcoming earnings report date?
Mind Medicine’s upcoming earnings report date is Nov 12, 2025 which is in 51 days.
How were Mind Medicine’s earnings last quarter?
Mind Medicine released its earnings results on Aug 05, 2025. The company reported -€0.426 earnings per share for the quarter, missing the consensus estimate of -€0.324 by -€0.102.
Is Mind Medicine overvalued?
According to Wall Street analysts Mind Medicine’s price is currently Undervalued.
Does Mind Medicine pay dividends?
Mind Medicine does not currently pay dividends.
What is Mind Medicine’s EPS estimate?
Mind Medicine’s EPS estimate is -0.43.
How many shares outstanding does Mind Medicine have?
Mind Medicine has 76,087,944 shares outstanding.
What happened to Mind Medicine’s price movement after its last earnings report?
Mind Medicine reported an EPS of -€0.426 in its last earnings report, missing expectations of -€0.324. Following the earnings report the stock price went up 2.117%.
Which hedge fund is a major shareholder of Mind Medicine?
Currently, no hedge funds are holding shares in DE:MMQ
Mind Medicine Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.16 (179.08% Upside)
$22.16 (179.08% Upside)
Blogger Sentiment
Bullish
DE:MMQ Sentiment 100%
Sector Average 72%
Sector Average 72%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.26%
12-Months-Change
Fundamentals
Return on Equity
-59.11%
Trailing 12-Months
Asset Growth
-1.14%
Trailing 12-Months
Company Description
Mind Medicine
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
MMQ Company Deck
MMQ Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook for MindMed, driven by strong enrollment in pivotal trials, financial stability, and strategic leadership additions. However, increased R&D expenses present a financial challenge, although they are aligned with the company's growth and trial activities.View all DE:MMQ earnings summariesMMQ Stock 12 Month Forecast
Average Price Target
€22.16
▲(179.08% Upside)
Technical Analysis
Altimmune
―
Sana Biotechnology
―
Verve Therapeutics
―
ATAI Life Sciences
―
Amylyx Pharmaceuticals Inc
―
Options Prices
Currently, No data available
---